Valuation

NVCRNovoCure Limited

StockNasdaqJerseyHealth careEU retail investors: available

−5.7% today · +4.8% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 8% of the instruments we score

Quality, Stability: among the weakest; priced higher than most peers. No dividend.

NovoCure Limited (NVCR) valuation against sector peers: P/B 3.9, free-cash-flow yield −1.8%, P/S 1.9.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricNVCRSector medianvs median
P/E—25.7 · n=26—
P/B3.93.6 · n=458% above
P/S1.94.7 · n=4059% below
EV/EBIT—22.6 · n=28—
Free-cash-flow yield−1.8%3.8% · n=39147% below
Dividend yield0.00%0.19% · n=99100% below
Return on equity−35.2%5.2% · n=56775% below
Return on invested capital−20.7%6.5% · n=47419% below
Gross margin77.0%70.2% · n=3910% above
Net debt / EBITDA—2.08 · n=25—

Value factor: 12 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NOVNNovartis AG22.46.818.75.6%2.8%10/10
NVSNovartis AG22.36.818.75.6%2.4%10/10
AZNAstraZeneca PLC28.35.922.84.1%1.2%5/10
AZNAstraZeneca plc28.35.922.84.1%1.7%6/10
NVONovo Nordisk A/S11.86.210.34.9%4.6%7/10
SNYSanofi13.41.518.26.9%4.3%7/10
SANSanofi SA13.41.518.26.9%4.8%9/10
GSKGSK plc14.55.111.87.7%3.5%9/10
TEVATeva Pharmaceutical Industries Limited97.86.243.32.5%0.0%6/10
ALCAlcon AG37.51.729.34.7%0.5%5/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 29 Oct 2026